Amarin Corp Plcuk (AMRN) Current Deferred Revenue (2013 - 2024)
Amarin Corp Plc\Uk (AMRN) posted quarterly Current Deferred Revenue of $4.4 million for Q1 2024, down 70.14% year-over-year from $14.9 million in Q2 2023, and down 8.27% quarter-over-quarter from $4.8 million in Q4 2023.
Amarin Corp Plcuk (AMRN) Current Deferred Revenue (2013 - 2024) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Current Deferred Revenue for 11 consecutive years, with $4.4 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Current Deferred Revenue fell 70.14% year-over-year to $4.4 million; the TTM figure through Mar 2024 stood at $4.4 million (down 70.14% YoY), while the FY2023 annual figure was $4.8 million, down 68.4% from the prior year.
- Current Deferred Revenue slipped to $4.4 million in Q1 2024 per AMRN's latest filing, from $4.8 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $21.8 million in Q1 2020 and bottomed at $92000.0 in Q3 2021.
- Historically, Current Deferred Revenue has averaged $12.7 million across 5 years, with a median of $15.7 million in 2022.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue plunged 97.55% — and 2022, when it jumped 16961.96%.
- Amarin Corp Plc\Uk's Current Deferred Revenue stood at $18.6 million in 2020, then dropped by 10.32% to $16.7 million in 2021, then decreased by 8.16% to $15.3 million in 2022, then plunged by 68.4% to $4.8 million in 2023, then dropped by 8.27% to $4.4 million in 2024.
- Business Quant data shows AMRN's Current Deferred Revenue at $4.4 million in Q1 2024, $4.8 million in Q4 2023, and $5.0 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 4.45 Mn |
| Dec 31, 2023 | 4.85 Mn |
| Sep 30, 2023 | 4.97 Mn |
| Jun 30, 2023 | 5.36 Mn |
| Mar 31, 2023 | 14.90 Mn |
| Dec 31, 2022 | 15.35 Mn |
| Sep 30, 2022 | 15.70 Mn |
| Jun 30, 2022 | 16.01 Mn |
| Mar 31, 2022 | 16.34 Mn |
| Dec 31, 2021 | 16.71 Mn |
| Sep 30, 2021 | 92,000.00 |
| Jun 30, 2021 | 17.97 Mn |
| Mar 31, 2021 | 17.97 Mn |
| Dec 31, 2020 | 18.63 Mn |
| Sep 30, 2020 | 3.75 Mn |
| Jun 30, 2020 | 20.21 Mn |
| Mar 31, 2020 | 21.81 Mn |
| Dec 31, 2019 | 20.85 Mn |
| Sep 30, 2019 | 19.58 Mn |
| Jun 30, 2019 | 19.74 Mn |